Focus on eptifibatide: GP IIb/IIIa inhibitor reduces complications of angioplasty, acute coronary syndrome

Formulary

Volumn 33, Issue 7, 1998, Pages 632-647

  Dunn, Alisha ^a   Chow, Moses S S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0032447483     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332:1553-9.
2. Integrilin (eptifibatide) Injection package insert. COR Therapeutics, Inc, South San Francisco, CA, and Key Pharmaceu-ticals, Inc, Kenilworth, NJ, May 1998.
3. Phillips SR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(Suppl 4A):11B-20B.
4. Tcheng JE, Lincoff AM, Sigmon KM, et al, for the IMPACT-II investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
5. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71:831-3.
6. Ohman EM, Harrington RA, Lincoff AM, et al. Early clinical experience with integrilin, an inhibitor the platelet glycoprotein IIb/IIIa receptor. Eur Heart J 1995;16(Suppl L):50-5.
7. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, Impact II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78(Suppl 3A):35-40.
8. Aggrastat (tirofiban HCl) Injection package insert. Merck & Co, West Point, PA, May 1998.
9. Charo IF, Scarborough RM, Wolf D. Pharmacodynamics of the GP IIb/IIIa antagonist integrilin: Phase I clinical studies in normal healthy volunteers [abstract]. Circulation 1992;86(Suppl I):I-260.
10. Topol EJ, Califf RM, Weisman HF, et al, on behalf of the EPIC investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at 6 months. Lancet 1994;343: 881-6.